DARE (Dare Bioscience, Inc. Common Stock) Stock Analysis - News
Dare Bioscience, Inc. Common Stock (DARE) is a publicly traded Healthcare sector company. As of May 21, 2026, DARE trades at $2.36 with a market cap of $31.61M and a P/E ratio of -2.46. DARE moved +5.11% today. Year to date, DARE is +17.09%; over the trailing twelve months it is -19.38%. Its 52-week range spans $1.27 to $9.19. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces DARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in DARE news today?
Dare Bioscience to Launch FloraSync LF5 in June, Seeks Additional Funding: Dare Bioscience plans to launch FloraSync LF5 in June 2026 as its first direct product revenue, targeting women’s health gaps while its topical arousal cream Dare to Play has faced state-specific registration delays. The firm relies on non-dilutive grants but lacks 12 months of capital and must raise funds.
Dare Bioscience to Launch FloraSync LF5 in June, Seeks Additional Funding: Dare Bioscience plans to launch FloraSync LF5 in June 2026 as its first direct product revenue, targeting women’s health gaps while its topical arousal cream Dare to Play has faced state-specific registration delays. The firm relies on non-dilutive grants but lacks 12 months of capital and must raise funds.
Does Rallies summarize DARE news?
Yes. Rallies summarizes DARE news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is DARE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DARE. It does not provide personalized investment advice.
